Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Integromics Partners with CITRE and CEIT

Published: Friday, April 19, 2013
Last Updated: Friday, April 19, 2013
Bookmark and Share
Venture attracts EUR 2 million grant for ‘new frontier’ of data interpretation for drug development.

Integromics® has announced that it has entered into a partnership with the Celgene Institute for Translational Research Europe (CITRE) and the Centre of Studies and Technical Research (CEIT), for the execution of SANSCRIPT, a project that aims at the development of new data analysis methods applied in clinical genomics studies.

Based on the strength of its R&D work, the new partnership has been awarded a EUR two million grant from the Spanish Government for the development of algorithms and statistical tools to identify alternative splicing events significantly related with disease associated biomarkers or therapeutic targets using RNA sequencing (RNA-seq).

Current algorithms, due to their intrinsic characteristics, have major limitations in characterizing gene alterations, which are frequently related to drug resistance and other phenotypes.

Therefore, it is essential to adapt the present methods developed for the new massive sequencing technologies to extract all their potential for development of diagnostic and prognostic tests, and drug discovery in the clinical and pharmaceutical environment.

The SANSCRIPT collaboration, coordinated by Integromics, has been designed to address these issues through the synergy between the engineers at CEIT, scientists at CITRE and the bioinformaticians from Integromics, which will undoubtedly accelerate the development of solutions for personalized medicine.

The new solutions will be validated for personalized-drug development processes where gene expression is essential to understand the differing responses to treatment.

The SANSCRIPT project represents an ideal opportunity for Integromics to reinforce its commitment to the development of software solutions for personalized medicine in the context of clinical studies.

“This is the first time that we can effectively work hand in hand with both an advanced software engineering team from a first class Technical Center and a research group from a leading biopharmaceutical corporation to cooperatively address an important gap”, said Eduardo González Couto, Chief Strategy Officer, Integromics. “The SANSCRIPT grant provides key financial support for us to spearhead the usage of NGS for drug development and help us make personalized medicine a reality.”

“Automated next-gen sequencers have increased the speed and reduced the cost of sequencing, making it possible to offer genetic testing to consumers. Producing the genomic data is not a problem anymore, while the analysis and interpretation of this data has become the ‘new hurdle’ ”, continues Dr. Gonzalez Couto.

Dr. Couto continued, “In order to identify the gene expression changes associated to sensitivity to treatment, including the detailed characterization of transcription isoforms for clinical usage, bioinformatics tools are crucially needed to design novel algorithms from the very beginning to be compatible with long reads from upcoming NGS technologies.”

"For us it is a pleasure to work with both a leading Spanish biosoftware company and a Pharma industry. This collaboration will help us to focus on a specific problem and provide a solution: algorithms that identify gene aberrations related to drug resistance in cancer” said Prof. Angel Rubio, Principal Investigator of the CEIT.

Prof. Rubio continued, “We are quite excited in working to improve the health: even though we have had other projects related with human health, they were not so ambitious as this one” concluded Prof. Rubio.

As genome sequencing continues to take footholds in diagnosis, prognosis and treatment of diseases, it is expected that the findings of the SANSCRIPT project, in terms of software and new methodologies, will enhance the reliability and significance of the next generation sequencing (NGS) technology in the pipelines of drug development and clinical genomics studies.

The results of SANSCRIPT will be made available through new releases of the Integromics’ OmicsOffice® software suite.

This will give clinical drug discovery scientists an immediate access to the fruits of the SANSCRIPT project, allowing them to apply new data analysis methods to their own studies.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Integromics Invests in the Optimization of Computing Performance for Bioinformatics Applications
Key collaboration with European experts of HPC to bring new big-data computing solutions into genomics.
Friday, March 22, 2013
Integromics Partners with FPGMX to Develop Low-Cost Methods for Clinical Genomics
Venture attracts EUR one million grant for ‘new frontier’ of data interpretation for medical usage.
Tuesday, February 07, 2012
Integromics and Ingenuity Expand their Co-operation with the Integration of a Fourth Integromics Product to Ingenuity’s IPA
Combined solutions to offer bridge between discovery and relevance of genomics and proteomics.
Thursday, April 07, 2011
Novel Polyadenylation Genome-wide Profiling Achieved using Next Generation Sequencing Software
A paper published in the journal Cell highlighting a novel genome wide profile of polyadenylation events in human and yeast, performed with Direct RNA Sequencing, demonstrated the importance of appropriate bioinformatics software in maximizing the value of the genomic data.
Monday, January 10, 2011
Integromics and TATAA Biocenter Collaborate to offer Comprehensive qPCR Data Analysis
The TATAA Biocenter is recommending Integromics’ RealTime StatMiner® as a complete solution for qPCR data analysis.
Monday, March 08, 2010
Scientific News
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Genes That Increase Children's Risk Of Blood Infection Identified
A team led by Oxford University has identified genes that make certain children more susceptible to invasive bacterial infections by performing a large genome-wide association study in African children.
Poverty Marks a Gene, Predicting Depression
New study of high-risk teens reveals a biological pathway for depression.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!